search
Back to results

IgM-Enriched Immunoglobulin for Neonatal Sepsis

Primary Purpose

Neonatal Sepsis, Early-Onset, Very Low Birth Weight Infant, Inflammation

Status
Unknown status
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
IgM-enriched IVIG
Sponsored by
Fakultas Kedokteran Universitas Indonesia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Neonatal Sepsis, Early-Onset focused on measuring IgM-enriched Intravenous Immunoglobulin

Eligibility Criteria

1 Minute - 1 Hour (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Very low birth weight infants (< 1500 g)
  • Gestational age below 32 weeks
  • Risk of Early-Onset sepsis from maternal and neonate factors
  • Inborn neonates

Exclusion Criteria:

  • Birth weight < 600 g
  • Gestational age < 26 weeks
  • Multiple Congenital Anomaly
  • Neonates with suspected congenital syndrome

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Treatment Group

    Placebo Group

    Arm Description

    IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics

    Antibiotics only

    Outcomes

    Primary Outcome Measures

    Early Mortality Rate
    Neonates in the treatment group should have lower mortality rate in the first week of life

    Secondary Outcome Measures

    Positive blood culture
    Neonates in the treatment group should have less number of positive blood culture than those in the place group
    Duration of NICU stay
    Neonates in the treatment group should be discharged earlier than those in the placebo group
    Quantitative CRP Levels
    Neonates in the treatment group should have lower CRP levels than those in the placebo group
    IT Ratio value
    Neonates in the treatment group should have lower IT Ratio value than those in the placebo group
    Leukocyte count
    Neonates in the treatment group should have lower Leukocyte count than those in the placebo group
    IgGAME (IgG, IgM, IgA, IgE) Levels
    Neonates in the treatment group should have higher IgGAME levels than those in the placebo group

    Full Information

    First Posted
    July 27, 2019
    Last Updated
    July 31, 2019
    Sponsor
    Fakultas Kedokteran Universitas Indonesia
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04041765
    Brief Title
    IgM-Enriched Immunoglobulin for Neonatal Sepsis
    Official Title
    Efficacy of Prophylactic IgM-Enriched Immunoglobulin for the Management of Early-Onset Neonatal Sepsis in Very Low Birth Weight Preterm Neonates; A Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 2019 (Anticipated)
    Primary Completion Date
    June 2020 (Anticipated)
    Study Completion Date
    August 2020 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Fakultas Kedokteran Universitas Indonesia

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This study compares giving prophylactic IgM enriched Intravenous Immunoglobulin (IVIG) with placebo in 1 hour after birth, in neonates with risk factors of Early-Onset Neonatal Sepsis (EONS). In addition to the intervention, standard regimen antibiotics are also given within 1 hour. The IVIG is given for 3 days and primary and secondary outcomes will be collected. Risk factors are both from maternal and neonate origin.
    Detailed Description
    This randomized-controlled trial conducted in Cipto Mangunkusumo Hospital, Jakarta, Indonesia aims to determine the efficacy of prophylactic IgM-Enriched IVIG in preventing EONS. A total of 70 very low birth weight (VLBW) neonates with risk factors for EONS including maternal factors of premature rupture of membrane (PROM), fever, urinary tract infection (UTI), chorioamnionitis, and neonatal factor of prematurity and resuscitation history will be collected. These neonates within 1 hour of life will then be administered either placebo or IgM-enriched IVIG 0.25g/kg/day for 3 days, in addition to first-line empiric antibiotic. Randomization is done using simple randomization. Triple masking (Participant, Investigator, Outcomes Assessor) is conducted. These neonates will then be clinically observed and evaluated for early mortality (mortality below 7 days), hemodynamics, length of stay, blood culture results, C-Reactive Protein (CRP), IT ratio, routine hematological examination, and IgGAME as parameters of improvement and prevention of EONS. STATA version 12 (Macintosh version) will be used for data management and statistical analyses. The variables will first be presented descriptively, continued with bivariate and multivariate analysis. Bivariate analysis will be conducted between independent and dependent variables using chi-square/Fisher's exact test, Student's t-test, and Kruskal-Wallis. Variables with p-values <0.25 will be included in the multivariate analysis using logistic regression. The investigators will use two-sided p-values in our analysis with a p < 0.05 level of significance.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Neonatal Sepsis, Early-Onset, Very Low Birth Weight Infant, Inflammation, Infant, Newborn, Disease
    Keywords
    IgM-enriched Intravenous Immunoglobulin

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    70 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment Group
    Arm Type
    Experimental
    Arm Description
    IgM-enriched IVIG given with dose of 0.25g/kg over 3 hours for 3 days in addition to Antibiotics
    Arm Title
    Placebo Group
    Arm Type
    Placebo Comparator
    Arm Description
    Antibiotics only
    Intervention Type
    Drug
    Intervention Name(s)
    IgM-enriched IVIG
    Other Intervention Name(s)
    Pentaglobin®
    Intervention Description
    Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
    Primary Outcome Measure Information:
    Title
    Early Mortality Rate
    Description
    Neonates in the treatment group should have lower mortality rate in the first week of life
    Time Frame
    1 week
    Secondary Outcome Measure Information:
    Title
    Positive blood culture
    Description
    Neonates in the treatment group should have less number of positive blood culture than those in the place group
    Time Frame
    1 week
    Title
    Duration of NICU stay
    Description
    Neonates in the treatment group should be discharged earlier than those in the placebo group
    Time Frame
    Through study completion, an average of 3 months
    Title
    Quantitative CRP Levels
    Description
    Neonates in the treatment group should have lower CRP levels than those in the placebo group
    Time Frame
    1 week
    Title
    IT Ratio value
    Description
    Neonates in the treatment group should have lower IT Ratio value than those in the placebo group
    Time Frame
    1 week
    Title
    Leukocyte count
    Description
    Neonates in the treatment group should have lower Leukocyte count than those in the placebo group
    Time Frame
    1 week
    Title
    IgGAME (IgG, IgM, IgA, IgE) Levels
    Description
    Neonates in the treatment group should have higher IgGAME levels than those in the placebo group
    Time Frame
    1 week

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Minute
    Maximum Age & Unit of Time
    1 Hour
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Very low birth weight infants (< 1500 g) Gestational age below 32 weeks Risk of Early-Onset sepsis from maternal and neonate factors Inborn neonates Exclusion Criteria: Birth weight < 600 g Gestational age < 26 weeks Multiple Congenital Anomaly Neonates with suspected congenital syndrome
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Rinawati Rohsiswatmo, MD, PhD
    Phone
    +62811133094
    Email
    rinarohsis@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Rinawati Rohsiswatmo, MD, PhD
    Organizational Affiliation
    Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Nina D Putri, MD, PhD
    Organizational Affiliation
    Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    24098953
    Citation
    Capasso L, Borrelli AC, Parrella C, Lama S, Ferrara T, Coppola C, Catania MR, Iula VD, Raimondi F. Are IgM-enriched immunoglobulins an effective adjuvant in septic VLBW infants? Ital J Pediatr. 2013 Oct 7;39:63. doi: 10.1186/1824-7288-39-63.
    Results Reference
    background
    PubMed Identifier
    3195529
    Citation
    Haque KN, Zaidi MH, Bahakim H. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child. 1988 Dec;142(12):1293-6. doi: 10.1001/archpedi.1988.02150120047038.
    Results Reference
    background
    PubMed Identifier
    15546815
    Citation
    Reith HB, Rauchschwalbe SK, Mittelkotter U, Engemann R, Thiede A, Arnold A, Lissner R. IgM-enriched immunoglobulin (pentaglobin) positively influences the course of post-surgical intra-abdominal infections. Eur J Med Res. 2004 Oct 29;9(10):479-84.
    Results Reference
    background
    PubMed Identifier
    29460549
    Citation
    Capasso L, Borrelli AC, Pirozzi MR, Bucci L, Albachiara R, Ferrara T, Raimondi F. IgM and IgA enriched polyclonal immunoglobulins reduce short term mortality in extremely low birth weight infants with sepsis: a retrospective cohort study. Minerva Pediatr (Torino). 2021 Feb;73(1):3-7. doi: 10.23736/S2724-5276.18.04850-8. Epub 2018 Feb 19.
    Results Reference
    background
    PubMed Identifier
    25220128
    Citation
    Capasso L, Borrelli AC, Ferrara T, Coppola C, Cerullo J, Izzo F, Caiazza R, Lama S, Raimondi F. Immunoglobulins in neonatal sepsis: has the final word been said? Early Hum Dev. 2014 Sep;90 Suppl 2:S47-9. doi: 10.1016/S0378-3782(14)50013-8.
    Results Reference
    background

    Learn more about this trial

    IgM-Enriched Immunoglobulin for Neonatal Sepsis

    We'll reach out to this number within 24 hrs